Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-210P is a human pseudogene corresponding to the U6 small nuclear RNA gene family. U6 snRNA itself is vital to the spliceosome, a ribonucleoprotein complex required for excision of introns during pre-mRNA splicing[3][1]. However, pseudogenes like RNU6-210P are nonfunctional gene copies that generally do not produce active or detectable RNA products. Vertebrate genomes have numerous U6-related pseudogenes, which reflect the evolutionary importance of the parent U6 snRNA gene but do not serve as direct functional targets or therapeutic entities in molecular medicine[3][2][6]. Summary of core facts: - RNU6-210P is a **pseudogene**, not a coding gene or drug target[2][6]. - It is not involved in any biological function or disease mechanism, nor is it a target for any drugs or used as a biomarker. - The entry is **incorrect** as a therapeutic target, and should not be interpreted as a valid molecular target for therapy or research. - Function and importance relates only to its parent gene, U6 snRNA[3][1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 210, pseudogene (RNU6-210P).